Page 38 of 1,034: studies 371 to 380 of 10,336, newest first. Back to the depression overview
The Brown University Psychopharmacology Update May 1, 2026
Patients with treatment‐resistant depression who received a series of treatments with ketamine or esketamine showed a substantial reduction in emergency department visits related to suicidality over a 6‐month period, a study has found. Study participants had a 56.7% response rate of depression symptoms following the acute phase of treatment.
Journal of Affective Disorders May 1, 2026 Michel Danon, Gabriela Ostronoff, Anne-Cécile Petit et al.
Regulatory approvals for intranasal esketamine in treatment-resistant depression (TRD) differ with respect to its indication for suicidal ideation. While rapid antidepressant effects are well documented, whether esketamine exerts an anti-suicidal effect independent of mood improvement remains unclear. In this two-center observational study, 261 adults with moderate-to-severe TRD at Sainte-Anne...
Journal of Clinical Psychopharmacology May 1, 2026 Matteo Carminati, Mattia Tondello, Chiara Morana et al.
Growing evidence links inflammation with major depressive disorder (MDD) and treatment resistance. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple peripheral marker of systemic inflammation and immune balance and it may capture clinically meaningful heterogeneity in inflammatory burden, potentially contributing to variability in antidepressant response and vulnerability to...
Nature Mental Health May 1, 2026 S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey et al. 2 citations
This study presents a living systematic review and open-data meta-analytic database from 15 randomized controlled trials examining the effects of psilocybin treatment on depressive symptoms. Existing evidence suggests that psilocybin treatment alleviates depressive symptoms. Depression is a major cause of disability worldwide, motivating interest in psilocybin as a potential treatment. Here we...
International Journal of Drug Delivery Technology April 30, 2026 Dr. Dheerendra Kumar, Dr. Praveen Sachan, Dr. Piyush Verma
Aim This study aims to compare two treatment procedures (standard selective serotonin reuptake inhibitors and rapid-acting therapies/specifically ketamine) for patients suffering from treatment-resistant depression along with evaluating the effectiveness of these approaches in alleviating symptoms and improving patient outcomes. Materials and Methods This study examined 80 patients suffering...
The Correction Welfare Society of Korea April 30, 2026 The Correction Welfare Society Of Korea, Jiwoong Song, Hyunsuk Han
This study aimed to examine the effects of body scan meditation on depression, anxiety, stress, and impulsivity among alcohol-related offenders. A total of 30 inmates from A correctional facility in Jeonbuk Province were randomly assigned to either an experimental group or a control group. The experimental group participated in six sessions of body scan meditation over a two-week period. The...
International Journal of Clinical Trials April 29, 2026 Nikapitiye Nandarathana, Jay K. Ranjan, Hari S. Asthana et al.
Background: Depression is a significant global public health challenge, and mindfulness-based cognitive therapy (MBCT) is an evidence-based secular intervention for depression; however, it incorporates partially Buddhist mindfulness practices. The Satipaṭṭhāna-based thought purification therapy (SB-TPT) is a structured, seven-week intervention that integrates systematic contemplation of the...
International Journal of Psychiatry in Clinical Practice April 29, 2026 David Eckert, Siegfried Kasper
The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...
Naunyn-Schmiedeberg's Archives of Pharmacology April 28, 2026 Yunsheng Liu, Rongde Zhong, Fenyong Yao et al.
Depression is a leading global health burden increasingly linked to dysregulation in glutamatergic signaling. Ionotropic glutamate receptors (iGluRs), including NMDA, AMPA, and kainate subtypes, have emerged as pivotal therapeutic targets. However, the rapid expansion of literature has led to a fragmented research landscape, creating an urgent need for a structured overview. This study aims to...
Journal of Affective Disorders April 28, 2026 Nesreen Sedeek, Carley Rivers, Lucas Williamson et al.
Ketamine produces rapid antidepressant effects in a subset of patients with treatment-resistant depression, yet neuroimaging findings have been difficult to integrate because studies differ in imaging modality, analytic approach, task context, and post-infusion timing. To address this, we conducted a multimodal synthesis of functional magnetic resonance imaging (fMRI) and positron emission...